Should You Invest In Dividend Delights GlaxoSmithKline plc, British American Tobacco plc & Persimmon plc?

Royston Wild analyses the investment prospects of GlaxoSmithKline plc (LON: GSK), British American Tobacco plc (LON: BATS) and Persimmon plc (LON: PSN).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Today I am looking at three FTSE stocks set to deliver stunning shareholder returns.

GlaxoSmithKline

Backed up by its stellar product pipeline, I believe GlaxoSmithKline (LSE: GSK) is a terrific bet for those seeking attractive income flows in the near term and beyond. Earlier this year the business vowed to shell out a dividend of 80p per share through to 2017, a target that yields an impressive 5.9%.

GlaxoSmithKline’s pledge underlines the confidence it has that its exciting product pipeline will offset the loss of key, revenues-driving labels looking ahead. The City expects earnings to have slipped for a fourth successive year in 2015 as generic competitors smash demand for critical medicines. But an 11% anticipated bounceback next year indicates the sterling potential created by GlaxoSmithKline’s R&D department.

The Brentford firm advised this month that US regulators had given the green light to its Nucala add-on product for severe asthma, while its ViiV Healthcare unit also reported promising Phase II data for its HIV treatments. With GlaxoSmithKline planning to submit up to 20 new regulatory filings within the next five years, I reckon long-term investors should enjoy splendid returns.

British American Tobacco

And like GlaxoSmithKline, I believe that the rising financial might of emerging regions should power revenue growth at British American Tobacco (LSE: BATS) in the coming years. These territories, and particularly those of Latin America, continue to cause the London firm a headache as adverse currency pressures weigh.

However, British American Tobacco is upping investment in its ‘Global Drive Brands’ such as Kent and Pall Mall, products that boast supreme pricing power, in order to drive long-term growth and offset these woes. And with good reason — volumes of these labels leapt 7.2% during January-September. With these brands gobbling up market share, the City expects the tobacco play to bounce from a 1% earnings decline in 2015 to punch a 7% advance next year.

And with British American Tobacco also bolstering its e-cigarette proposition, a market spearheaded by its Vype technology, the business is in great shape to keep its progressive payout policy trucking. Indeed, a projected dividend of 155.7p per share for this year produces a chunky 4.2% yield, and this figure edges to 4.4% for 2016 amid predictions of a 163.3p reward.

Persimmon

Due to the steady flow of positive data coming from the UK housing sector, I believe construction specialists such as Persimmon (LSE: PSN) should deliver chunky returns in the years ahead. Just yesterday the ONS announced that the average home price leapt 6.1% year-on-year in September, speeding up from 5.5% in the previous month and driven by resplendent buyer demand.

And Persimmon announced this month that buying activity had strengthened entering the autumn period, with private sales rates rising 12% between mid-August and the start of November, accelerating from 5% over the summer. Although this reflects the traditional seasonality of the market to some degree, a backcloth of favourable lending conditions, low interest rates and improving customer affordability should keep home sales motoring higher, in my opinion.

 Consequently Persimmon is expected to see earnings rocket 26% and 10% higher in 2015 and 2016 correspondingly, a terrific omen for dividends during the period. Indeed, the calculator bashers expect the housebuilder to deliver a payment of 99.6p per share in 2015, yielding a brilliant 5.5%. And a 107.4p dividend forecast for next year produces an exceptional 5.9% yield. I believe dividends should keep on thriving as the British housing crunch persists.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild has no position in any shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Illustration of flames over a black background
Investing Articles

2 red-hot UK growth stocks to consider buying in April

These two growth stocks are performing well, but can they continue to deliver for investors through 2024 and beyond?

Read more »

Charticle

Is JD Sports Fashion one of the FTSE 100’s best value stocks? Here’s what the charts say!

The JD Sports Fashion share price remains a wild ride during the first quarter. Could it be one of the…

Read more »

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »